Jacobs Levy Equity Management, Inc Outlook Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.22 - $2.03 $142,742 - $237,514	-117,002 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.27 - $2.23 $78,099 - $137,136	-61,496 Reduced 34.45%	117,002 $159,000
Q1 2021 May 17, 2021	SELL	$0.94 - $3.31 $92,203 - $324,674	-98,089 Reduced 35.46%	178,498 $402,000
Q4 2020 Feb 16, 2021	SELL	$0.7 - $1.58 $12,704 - $28,675	-18,149 Reduced 6.16%	276,587 $360,000
Q3 2020 Nov 16, 2020	BUY	$0.61 - $1.6 $179,788 - $471,577	294,736 New	294,736 $212,000

67.1K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.6B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.